# Multi-omic and functional screening reveal targetable vulnerabilities in *TP53* mutated multiple myeloma

Short title: Novel vulnerabilities in TP53 mutated myeloma

Dimitrios Tsallos<sup>1</sup>, Nemo Ikonen<sup>1</sup>, Juho J. Miettinen<sup>1</sup>, Muntasir Mamun Majumder<sup>1</sup>, Samuli Eldfors<sup>1,2</sup>, Imre Västrik<sup>1</sup>, Alun Parsons<sup>1</sup>, Minna Suvela<sup>1</sup>, Katie Dunphy<sup>3</sup>, Paul Dowling<sup>3</sup>, Despina Bazou<sup>4</sup>, Peter O'Gorman<sup>5</sup>, Juha Lievonen<sup>6</sup>, Raija Silvennoinen<sup>6</sup>, Pekka Anttila<sup>6</sup>, Caroline A. Heckman<sup>1</sup>

1. Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland;

2. Massachusetts General Hospital Cancer Center, Charlestown, MA, and Department of Medicine, Harvard Medical School, Boston, MA, USA;

3. Department of Biology, Maynooth University, W23 F2K8, Maynooth, Ireland;

4. School of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland;

5. Department of Haematology, Mater Misericordiae University Hospital, D07 WKW8, Dublin, Ireland;

6. Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, University

of Helsinki, Helsinki, Finland

#### **Corresponding author:**

Caroline A. Heckman, PhD Institute for Molecular Medicine Finland – FIMM University of Helsinki Tukholmankatu 8 (P.O. Box 20) FI-00290 Helsinki Finland c: +358 50 4156769 caroline.heckman@helsinki.fi

Abstract: 234 words Text: 4324 words Figures: 7 (5 figures and 2 tables)

**References:** 40 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 1 KEY POINTS

*TP53* mutation in myeloma confers sensitivity to multiple compounds, including approved
drugs, irrespective of del(17p) status.

4

5 *TP53* mutated myeloma links to higher expression of drug targets involved in cell proliferation,

- 6 mRNA processing, and chromatin modulation.
- 7

#### 8 ABSTRACT

9 Despite development of several effective therapies for multiple myeloma (MM), the prognosis 10 of patients with partial deletion of chromosome 17 (del(17p)) and TP53 aberrations remains poor. By applying comprehensive multi-omics profiling analyses (whole exome and 11 12 transcriptome sequencing plus proteomics) and functional ex vivo drug screening to samples from 167 patients with MM, we uncovered novel therapeutic vulnerabilities 13 14 specific to TP53 mutated MM. Our findings revealed a distinct sensitivity profile to a range of inhibitors (mitotic, topoisomerase, HDAC, HSP90, IGF1R and PI3K/AKT/mTOR 15 16 inhibitors) irrespective of 17p deletion status. Conversely, no increase in sensitivity was 17 observed for monoallelic TP53 (del(17p) with WT TP53) when compared to other 18 samples, highlighting the remaining unmet clinical need. Notably, plicamycin, an RNA 19 synthesis inhibitor linked to modulation of chromatin structure and increased 20 transcription, emerged as particularly efficacious for *TP53* mutated MM. The increased 21 sensitivity correlated with higher protein expression of the drug targets: HDAC2, HSP90AA1 and multiple ribosomal subunits. Additionally, we observed increased RNA 22 23 expression of G2M checkpoint, E2F targets and mTORC1 signaling in our cohort and the 24 MMRF-CoMMpass (NCT01454297) study in TP53 mutated MM. Harmonization of multiomics data with ex vivo drug screening results revealed that TP53 mutated MM is 25 26 functionally distinct from MM with monoallelic TP53, and demonstrates that MM with 27 mutated TP53, with and without del(17p), may be targetable by approved drugs. These results further indicate the need for regular monitoring by sequencing to identify these patients. 28

## 29 INTRODUCTION

Multiple myeloma (MM) is a complex and incurable disease characterized by a clonal 30 31 proliferation of plasma cells in the bone marrow (BM). Significant advancements in MM 32 treatment modalities have been made over the past decades<sup>1</sup>, but despite the availability of novel treatments, the clinical and genetic heterogeneity of the disease continues to 33 complicate prognosis and therapeutic strategies<sup>1</sup>. Genetic aberrations traditionally detected 34 by fluorescence *in situ* hybridization (FISH) are known to play a pivotal role in MM progression 35 36 and treatment outcomes<sup>2</sup>. Transitioning from FISH to next generation sequencing (NGS) could enhance the detection of recurrent aberrations to driver genes such as TP53, offering a more 37 38 comprehensive genomic landscape and potentially refining therapeutic approaches and 39 management of patients with MM<sup>2</sup>.

40 Among the genetic aberrations influencing MM prognosis, deletion of the p arm of chromosome 17, del(17p), stands out as a high-risk factor with profound implications for 41 patient prognosis and response to treatment<sup>2,3</sup>. Del(17p) is identified in 10% of patients with 42 43 newly diagnosed MM and is primarily monoallelic. Importantly, the TP53 gene is located within the minimally deleted region on 17p13. The co-occurrence of del(17p) together with 44 45 TP53 mutation, often referred to as 'double hit' MM, is associated with worse prognosis<sup>2,3</sup>. TP53 mutations alone are detected in 1-7% of newly diagnosed patients with MM<sup>4–6</sup>. However, 46 47 both TP53 mutation and del(17p) aberrations are more prevalent after relapse occurring in approximately 23-45% of cases<sup>5,7</sup>. The emergence of *TP53* mutations as a key risk factor for 48 stratification is evident given the significant adverse prognosis, even in the absence of 49 del(17p)<sup>6,8</sup>. Moreover, TP53 mutations in various cancers can lead to gain-of-function or 50 dominant negative phenotypes, altering treatment response<sup>9</sup>. 51

52 Functional ex vivo drug sensitivity testing of patients' tumor cells to hundreds of inhibitors can reveal cell dependencies and molecular vulnerabilities while accounting for patient 53 54 variability<sup>10–13</sup>. Here we show that integration of drug sensitivity data with genomic, transcriptomic, and proteomic data from the same samples revealed a deeper functional view 55 56 of the impact of TP53 aberrations in CD138+ MM cells. The presence of TP53 mutation 57 associated with increased sensitivity to approved drugs, including conventional chemotherapeutics, irrespective of del(17p) status. In contrast, monoallelic TP53 samples had 58 59 a distinct molecular profile without a significant change in *ex vivo* drug responses. Overall, we 60 explored novel therapeutic options for TP53 aberrations in MM and identified vulnerabilities

3

- associated with *TP53* mutation to multiple compounds, providing a foundation for targeted
  treatment strategies to improve patient outcome.
- 63

## 64 MATERIALS AND METHODS

#### 65 Patients and samples

Bone marrow (BM) aspirates and skin biopsies were collected from patients under approved 66 protocols (239/13/03/00/2010 and 303/13/03/01/2011) in line with the Declaration of 67 Helsinki as previously described<sup>10</sup>. Following Ficoll (GE Healthcare) gradient separation of the 68 mononuclear cell fraction, CD138+ cells were enriched by immunomagnetic bead separation 69 70 (StemCell Technologies) and used for downstream assays. Interphase FISH was conducted according to the European Myeloma Network 2012 guidelines<sup>29</sup>. Patient characteristics and 71 72 assays performed are detailed in Table 1. 73 Ex vivo drug screening and analysis

Drug sensitivity testing was conducted using an established *ex vivo* drug screening method on
 CD138+ cells, with viability measured by CellTiter-Glo reagent (Promega) after 72 hours<sup>10–12</sup>.
 BM CD138+ cells were added to pre-drugged plates, which contained up to 348 compounds
 (supplemental Table 1). Quality control analysis, dose response curve fitting, and drug
 sensitivity scores (DSS) were calculated as previously described<sup>15</sup>.

# 79 Whole Exome Sequencing

6 Genomic DNA was extracted from skin biopsies and CD138+ BM cells using the Qiagen DNeasy Blood & Tissue kit or the Qiagen AllPrep DNA/RNA/miRNA Universal kit. The isolated DNA was processed, exome libraries prepared and sequenced as described previously<sup>11,31</sup>. Somatic mutations were identified and annotated using established methods<sup>32</sup>. The presence of a mutation is considered if the variant frequency exceeded 5% (somatic p-value  $\leq$  0.05).

# 85 **RNA Sequencing**

86 RNA from CD138+ cells isolated using the Qiagen AllPrep DNA/RNA/miRNA Universal kit, 87 RNAseq libraries were prepared using ribosome depletion, data pre-processing and the 88 analysis pipeline were carried out as described earlier<sup>33</sup>. Differential gene expression (DGE) 89 analysis was performed using DESeq2 R package (1.36.0)<sup>34</sup> from log<sub>2</sub>CPM raw counts 90 calculated with edgeR after TMM normalized. Within DESeq2, raw count data were filtered 91 to remove genes with less than 10 reads in at least 95% of the samples. For the gene set

92 enrichment analysis, we used clusterProfiler (4.4.4)<sup>35</sup> package and MSigDB (7.5.1) and from
 93 that H (Hallmark) and C5 (GO) genesets, excluding human phenotype ontology sets (HPO)
 94 <sup>36,37</sup>.

#### 95 Label-Free LC-MS/MS Analysis and Data Processing of CD138+ cells

96 500 ng of each digested sample was analysed using Q-Exactive (ThermoFisher Scientific, 97 Hemel Hempstead, UK) high-resolution accurate mass spectrometer connected to a Dionex 98 Ultimate 3000 (RSLCnano) chromatography system (ThermoFisher Scientific, Hemel 99 Hempstead, UK). Peptides were separated and data acquired with MS/MS scans. Protein 100 identification and label-free quantification (LFQ) normalization were performed using 101 MaxQuant v1.5.2.8 (<u>http://www.maxquant.org</u>), with subsequent data analysis using 102 Perseus. In our figures, uniprot accession IDs are presented as gene symbol IDs. More details

# are provided in the **supplemental Methods**.

# 104 Validation using public data

We utilized the IA21 version of the MMRF-CoMMpass study (NCT01454297), available from
 MMRF research gateway (https://research.themmrf.org/). Only CD138+ BM samples at
 diagnosis were selected. The del(17p) status was determined using available seqFISH data<sup>38</sup>.
 DGE analysis was performed as described above. Survival analysis was performed in R using

109 survival  $(3.5-7)^{39}$  and survminer  $(0.4.9)^{40}$  packages.

# 110 Statistical Analyses

Statistical analysis was done in R. Normality of the data was assessed using Shapiro-Wilk test and based on the result either the Welch Two Sample t-test or Wilcoxon rank-sum test were applied to subsequent analysis. Categorical data was analyzed using Fisher's exact test or chisquare test according to the sample size. Kruskal-Wallis Test was applied to estimate the difference between the age distribution of the groups. Resulted p-values were adjusted with Benjamini-Hochberg. Survival analysis employed the Kaplan-Meier method and Cox proportional hazards models.

118

#### 119 **RESULTS**

#### 120 Study sample characteristics

Our study utilized data from 167 individuals receiving treatment throughout Finland.Collected BM samples were processed for mononuclear cell selection and immunomagnetic

separation of CD138+ cells. DNA from the selected cells and a matching skin biopsy underwent whole exome sequencing to identify somatic mutations. Subsets of CD138+ cells were also used for bulk RNA sequencing and proteomic evaluation (Figure 1A, B). Additionally, the *ex vivo* sensitivity of the same CD138+ MM patient cells was assessed against an oncology drug collection of 348 small molecule inhibitors, with 153 total screened samples (supplemental Table S1). Other clinical data, such as karyotyping, was available and summarized information is provided in Table 1.

- 130 When focusing on TP53 aberrations, the use of next-generation sequencing provides a more 131 detailed view of the patient subpopulations as presented in the MMRF-CoMMpass cohort 132 (Figure 1C). Characteristically, TP53 mutation becomes more prevalent at relapse (15.2%) 133 compared to diagnosis (7.2%). Given that mutated TP53 leads to functional impairment of wild-type (WT) p53 protein<sup>9,14</sup>, we grouped all samples with *TP53* mutation (*TP53*<sup>mut/-</sup> and 134 *TP53*<sup>mut/WT</sup>) in one category. This includes samples with additional detection of del(17p), also 135 136 known as double-hit MM. Samples containing only wild-type copies of TP53 but presented del(17p) from karyotyping are referred to as monoallelic TP53 from here on. Five samples 137 138 lacking sequencing results but with a detected del(17p) karyotype are also included in this 139 category, for a total of 19 monoallelic TP53 patient samples. The remaining samples (n = 130) 140 were TP53 WT.
- 141

#### 142 Presence of TP53 mutation is associated with increased sensitivity to multiple drugs

143 In search of novel therapeutic vulnerabilities in high-risk patients harboring TP53 aberrations, 144 we analyzed data from our *ex vivo* drug screening platform. To measure the drug sensitivity of 145 the samples, we used the drug sensitivity score (DSS), which is a modified version of the area 146 under the curve. The DSS allows for comparison of dose-response curves across a range of concentrations, providing a single measure of the sensitivity of the cancer cells to the drug<sup>15</sup>. 147 148 Confirming the difficulty to treat del(17p) patients, CD138+ MM cells with monoallelic TP53 149 showed no significant increase in ex vivo sensitivity to the tested compounds. Conversely, 150 samples with TP53 mutation, regardless of the presence of del(17p), displayed higher 151 sensitivity to certain mitotic inhibitors and inhibitors targeting RNA synthesis, HDAC, topoisomerase, HSP90, and the PI3K/AKT/mTOR pathway (Figure 2A,B; supplemental Table 152 153 s2). The mutant p53 targeting compound APR-246 demonstrated enhanced activity in TP53

154 mutated MM, suggesting that it effectively reactivates the mutant p53 protein leading to cell death. The biological significance of the specific grouping is also observed for monoallelic TP53 155 156 MM where increased resistance to the MDM2 antagonists idasanutlin (median difference = -157 6.8; p-value = 0.074) and nutlin-3 (median difference = -2.6; p-value = 0.014) was observed. Resistance to MDM2 antagonists suggests the reduced availability of p53 in samples with 158 monoallelic TP53, while the activity of APR-246 highlights the dominant effect of the mutant 159 p53 protein (Figure 2C). The impact of *TP53* mutation on *ex vivo* drug response is highlighted 160 161 by the comparison of DSS between TP53 mutated and monoallelic TP53 samples (supplemental Figure S1). 162

163 The most remarkable increase in sensitivity of TP53 mutated MM samples was observed for 164 plicamycin, an RNA synthesis inhibitor. The response to plicamycin was greater than that to 165 another RNA and DNA synthesis inhibitor, dactinomycin, which also showed a significant increase in activity. Multiple conventional chemotherapeutics showed increased activity in 166 167 samples with TP53 mutation, specifically mitotic inhibitors (vinorelbine, paclitaxel, docetaxel, 168 vincristine, ABT-751, patupilone) and topoisomerase inhibitors (teniposide, irinotecan, 169 daunarubicin, camptothecin, topotecan, etoposide, doxorubicin, idarubicin). Many 170 chemotherapeutics were tested on fewer samples, however, the consistency of the increased 171 sensitivity on similar compounds supports the observation that TP53 mutated cells are more 172 sensitive to these drug classes (supplemental Table S2).

This increased activity was also evident with HDAC inhibitors quisinostat and panobinostat, both approved treatments. In a smaller set of samples, CUDC-101, targeting class I/II HDAC and EGFR also showed significantly increased activity in *TP53* mutated MM samples, while belinostat showed increased, but not a significant difference in activity (median difference = 9.5; p-value = 0.072).

The heightened activity of PI3K/AKT/mTOR pathway inhibitors in *TP53* mutated MM CD138+ cells suggested a potential dependency on growth signals involving this pathway. We showed increased *ex vivo* sensitivity to vistusertib, omipalisib, pictilisib, temsirolimus, and dactolisib. Additionally, kinase inhibitors tirbanibulin, GSK-1904529A, BMS-754807, and ruxolitinib all demonstrated increased activity in *TP53* mutated MM samples. GSK-1904529A and BMS-754807 target IGF1-R and ruxolitinib specifically targets JAK1 and JAK2 kinases, which are upstream of PI3K, AKT and mTOR. The HSP90 inhibitor tanespimycin, which indirectly 185 suppresses the PI3K/AKT/mTOR pathway<sup>16</sup>, also showed significant increase in activity
186 towards *TP53* mutated CD138+ cells.

To assess the impact of *TP53* mutation frequency on the response to these compounds, we correlated the response of each sample with the mutation frequency (**supplemental Figure S2; supplemental Table S3**). To establish correlation, we selected compounds tested in at least 5 samples and highlighted compounds with significant difference observed in *TP53* mutated MM (**supplemental Figure S2A**). Except for JQ1, most compounds showed weak and nonsignificant correlation to mutation frequency, probably owing to overall limited selective toxicity of the compounds.

194

## 195 TP53 mutations frequently co-occur with KRAS mutations in MM

196 To understand the broader genetic landscape of TP53 aberrations in MM and search for 197 possible confounding factors in drug response, we explored the frequency of co-occurrence 198 of common mutations. In our cohort, almost half of the samples with TP53 mutation also had 199 a mutation to KRAS, while KRAS mutations were rare in samples with monoallelic TP53 200 (Fisher's exact test: p = 0.029; OR = 6.44, 95% CI = [1.01, 73.93]; Figure 3A). However, KRAS mutations were not more likely to be present in TP53 mutated MM compared to MM with 201 202 WT *TP53* (Fisher's exact test: p = 0.080; OR = 0.378, 95% CI = [0.12, 1.21]). To assess whether 203 TP53 and KRAS mutation co-occurrence is common in MM, we analyzed diagnostic samples 204 from the MMRF-CoMMpass study (Figure 3B). In this cohort, KRAS mutations were present in 205 14 out of 85 samples with TP53 mutation (16.5% frequency), which was more common than with WT TP53 ( $\chi^2$  = 5.089, df = 2, p-value = 0.024). To assess the impact of co-occurring KRAS 206 207 mutations on ex vivo drug response, we compared the drug sensitivity profiles of TP53 208 mutated MM with and without KRAS mutation. We found that samples with co-occurring 209 TP53 and KRAS mutations were significantly more resistant to 5 compounds compared to 210 samples with mutated TP53 and WT KRAS (supplemental Figure S3, supplemental Table S4). 211 TP53 is often characterized by hotspot mutations, with the location of the mutation having 212 different functional impact on the resulting protein. Using the MMRF-CoMMpass dataset, we 213 found that most mutations in TP53 were spread across the protein but occurred more 214 frequently in the DNA binding domain (Figure 2C). Similarly, in the FIMM cohort, most 215 mutations occurred in the DNA binding domain, with some samples containing more than one

mutation (Table 2). No other hotspot mutation was detected, in concordance with previous
 observations in MM<sup>17</sup>.

218

# 219 Differential gene expression analysis reveals a transcriptional profile of enhanced cellular 220 proliferation in TP53 mutated MM

To understand the cellular implications and functional impact of *TP53* mutations in MM, we compared RNA sequencing data of *TP53* mutated to WT *TP53* MM samples and applied differential gene expression (DGE) followed by gene set enrichment analysis (GSEA). To explore the consistency of our analysis with a wider cohort, we followed the same steps using data both from the FIMM cohort as well as the MMRF-CoMMpass study.

In the FIMM cohort, we compared 15 samples with TP53 mutation against 77 WT TP53 226 227 samples, from which we identified 1043 differentially expressed genes (p-value  $\leq$  0.05), of 228 which 675 were upregulated and 368 downregulated (Figure 4A; supplemental Tables S5-S7). 229 From the CoMMpass study samples with RNA sequencing data available, we compared 52 samples exhibiting TP53 mutation (8.6%) against 552 samples with WT TP53. This DGE analysis 230 231 provided 700 differentially expressed genes (adjusted p-value  $\leq$  0.01), of which 458 were upregulated and 232 downregulated (Figure 4B, supplemental Tables S8-S10). The results 232 233 from both datasets were consistent and demonstrated that TP53 mutated MM is associated 234 with cell proliferation gene expression signatures. The G2M checkpoint, E2F targets and mitotic spindle formation were upregulated in both cohorts (Figure 4C, D). In addition to the 235 236 common findings, the CoMMpass dataset showed a significant upregulation of mTORC1 237 signaling and genes involved in glycolysis. On the other hand, the downregulation of gene sets 238 modulated by NF- $\kappa$ B in response to TNFalpha, hypoxia, response to interferon gamma, and 239 apoptosis were only significant in the FIMM cohort analysis.

Additionally, we explored the transcriptional impact of monoallelic *TP53* on both FIMM and CoMMpass cohorts. DGE analysis of the FIMM cohort identified 724 differentially expressed genes (p-value  $\leq$  0.05), of which 472 were upregulated and 252 downregulated (**supplemental Figure S4A**). From the CoMMpass study samples, we identified 430 differentially expressed genes (adjusted p-value  $\leq$  0.05), of which 230 were upregulated and 200 downregulated (**supplemental Figure S4B**). GSEA revealed an increase in the G2M and E2F gene sets for

samples with monoallelic *TP53* only in the larger CoMMpass cohort (supplemental Figure
S4C; supplemental Tables S11-S13).

248

#### 249 Proteomic profiling reveals elevated drug target expression in TP53 mutated MM

To expand on our understanding of the functional molecular landscape associated with *TP53* mutations in MM, we explored proteomic data produced by LC-MS/MS analysis of CD138+ cells from a subset of our samples. We performed proteomic analysis on 34 samples, of which 5 contained *TP53* mutation, 6 had monoallelic *TP53* and 23 were WT *TP53*. Out of the 2753 identified proteins, 430 exhibited significant difference between samples with *TP53* mutation compared to WT *TP53* (Welch Two Sample t-test two sided; p-value  $\leq$  0.05; **Figure 5A**; **supplemental Table S14**).

257 In alignment with the results from GSEA of RNA sequence data, we observed an enrichment 258 of E2F targets and G2M checkpoint proteins. Additionally, MYC targets were upregulated as 259 shown in Figure 5B. Analysis using the Gene Ontology (GO) C5 library revealed significant enrichment of proteins associated with transcription processes, such as RNA binding, 260 RNA/mRNA processing, nuclear speckles, and RNA splicing (Figure 5C). Notably, the 261 262 ribonucleoprotein complex gene set, involved in ribosomal functions, including HURNPA3, 263 HNRNPA2B1, SNRPA1, and RNPS1, along with the FACT complex proteins SSRP1 and SUPT16H, were highly expressed in the TP53 mutated samples (Figure 5A; supplemental Table 264 265 **S14**). Among the gene sets enriched with the selected proteins, we observed downregulation 266 in the immune response and immune markers CD9, CD36 and CD76 suggesting a mechanism of immune evasion. Other significantly downregulated gene sets included those associated 267 268 with mechanisms of adhesion and secretion. For the full list of gene sets enriched in this 269 analysis see supplemental Tables S15-S16.

Among the significantly expressed proteins identified, some are notable drug targets. We observed increased expression of HDAC2, which is a target of HDAC inhibitors. This supports the observed sensitivity to specific HDAC inhibitors, including the approved non-selective inhibitors panobinostat and quisinostat, and the dual-acting inhibitor CUDC-101, which targets both HDAC and EGFR pathways. Similarly, we observed significant upregulation of HSP90AA1, the target of HSP90 inhibitor tanespimycin (**supplemental Figure S5**; **supplemental Table S2**). While these single proteins can explain the efficacy of some targeted

compounds, the scope is limited by the specificity of the inhibitors and the detectable proteinsin our analysis.

In contrast, comparison of monoallelic *TP53* to WT *TP53* proteomic profiles exhibited 96
 significantly expressed proteins, with 45 upregulated and 51 downregulated in the
 monoallelic *TP53* samples. We observed an increase in gene sets related to protein transport
 and a decrease in mitochondrial matrix and ribonucleoprotein complex (supplemental Figure
 S6; supplemental Tables S17-S18).

284

#### 285 Clinical Implications of TP53 aberrations

To translate our findings to the clinic and evaluate the impact on prognosis of *TP53* mutations, we leveraged the comprehensive dataset provided by the MMRF-CoMMpass study and investigated the clinical prognosis of patients with or without *TP53* mutation.

289 A significant reduction in overall survival (OS) was notable among patients with TP53 290 mutation as compared to those with WT TP53 (OS: HR = 2.004 [95% CI: 1.314-3.057] p = 0.001; 291 Figure 5D). Surprisingly, patients with monoallelic loss of TP53 showed no significant reduction in OS compared to patients with WT TP53, but they clearly had shorter progression 292 293 free survival (OS: HR = 1.264 [95% CI: 0.681-2.343] p = 0.458; PFS: HR = 1.356 [95% CI: 0.997-294 1.846] p = 0.053; Figure 5E). Patients with monoallelic *TP53* had a median PFS of 530 days (17.4 months) compared to 628 (20.6 months) for patients with TP53 mutation. This suggests 295 that the presence of TP53 mutation can lead to a more aggressive disease after the first 296 297 relapse, possibly because of clonal expansion. Although there is an increase in patients with 298 TP53 mutation at relapse (Figure 1), due to lack of variant allele frequency data in the MMRF-299 CoMMpass dataset we were not able to explore the clonal evolution of *TP53* mutations.

300

## 301 **DISCUSSION**

In our study we provide a comprehensive view and contribute significant insight into the consequences of *TP53* aberrations in MM by applying a multi-omic approach to a large set of patient samples. Functional assessment by *ex vivo* drug sensitivity testing along with genomic, transcriptomic, and proteomic analyses highlight the biological impact of *TP53* mutations and revealed potential treatment vulnerabilities. Notably, our findings discerned distinct differences in *ex vivo* drug responses between MM with *TP53* mutation and MM with

308 monoallelic *TP53* when compared to samples with WT diploid *TP53*. These results were 309 further supported by differences in the genomic, transcriptomic, and proteomic landscapes of 310 these patients. Our research provides novel insights into the vulnerabilities of MM with *TP53* 311 mutations, with or without del(17p), as well as underscoring the need and suggesting 312 potential personalized therapeutic strategies for this high-risk subset of patients for future 313 investigations.

The clinical landscape of MM has long been influenced by the presence of del(17p), a well-314 documented adverse prognostic factor<sup>2</sup>. With the advent of sequencing technologies, *TP53* 315 316 mutations have emerged as a novel prognosis marker in MM<sup>6,17</sup>, yet their distinct functional 317 impact compared to del(17p) has not been fully recognized until now. Our study showed that 318 unlike monoallelic TP53, TP53 mutations in CD138+ cells confer increased sensitivity to 319 multiple small molecule inhibitors. This finding presents opportunities to develop effective treatment strategies that includes conventional chemotherapies and other approved drugs. 320 321 By focusing on patients with TP53 mutation, we have the potential to mitigate the risk for 322 almost half of the del(17p) cases, including those with double-hit MM and those with TP53 323 mutation and intact chromosome 17. However, our results reaffirm the continued challenges 324 of treating del(17p) MM.

325 Drug sensitivity testing of MM samples from a large cohort of patients demonstrated that MM 326 with TP53 mutation is vulnerable to multiple approved and investigational drugs with known 327 target profiles. Even at low variant allele frequency (VAF) CD138+ MM cells with a minimum TP53 mutation VAF of 5% displayed increased sensitivity to a spectrum of compounds, 328 329 including conventional chemotherapeutics, topoisomerase, RNA synthesis, HDAC, HSP90, 330 IGF1R and PI3K/AKT/mTOR pathway inhibitors. HSP90 and HDAC inhibitors have already been 331 described to have critical roles in the degradation of mutant *TP53* in other types of cancer<sup>18</sup>. The increased expression of proteins HSP90AA1 and HDAC2, together with the increased 332 333 sensitivity to HSP90 and HDAC inhibitors, suggest a critical role for these factors in TP53 mutated MM cell survival. TP53 mutations have been previously reported to upregulate IGF1R 334 expression and IGF-1 mediated mitogenesis, possibly through reduced p53 levels and 335 increased demand for new ribosomes, leading to MDM2-p53 interaction<sup>19,20</sup>. Subsequent 336 mTOR pathway activation leads to increased cell proliferation, increased mRNA translation 337 338 and increased glycolytic activity<sup>19–21</sup>. The observed increase in expression of ribosomal

subunits, together with the enrichment of genes involved in glycolysis and mTORC1 signaling
may explain the enhanced vulnerability to IGF1R, PI3K/AKT/mTOR inhibitors.

Both gene expression and proteomic analyses showed enrichment of pathways associated with increased cell proliferation in *TP53* mutated MM. Consequently, common chemotherapies including mitotic inhibitors (i.e. paclitaxel and vincristine), intercalating agents (i.e. doxorubicin and gemcitabine) and topoisomerase inhibitors (i.e. topotecan, etoposide and idarubicin) showed increased activity in CD138+ cells with *TP53* mutation. In contrast, CD138+ cells with monoallelic *TP53* did not display an increase in sensitivity to chemotherapies when compared to cells from patients with WT *TP53*.

348 The enhanced sensitivity of TP53 mutated samples to doxorubicin, plicamycin and 349 dactinomycin may be explained by their mechanisms of action and association with ribosomal biogenesis and mRNA processing<sup>22,23</sup>. Proteomic analysis revealed that proteins belonging to 350 351 the ribonucleoprotein complex are upregulated in mutated TP53 and downregulated in 352 monoallelic TP53 MM. Doxorubicin has been previously shown to inhibit the synthesis of 47S rRNA precursor<sup>23</sup>, while it also acts as intercalator similarly to daunorubicin and idarubicin. 353 354 The RNA synthesis inhibitor plicamycin showed the largest difference in activity between TP53 355 mutated and WT TP53 samples. Plicamycin selectively targets genes with GC-rich promoter sequences, activates any remaining wild-type p53 and inhibits the transcriptional regulator 356 357 SP1 from DNA binding, including to the promoter of *TP53*<sup>23</sup>. The enrichment of pathways associated with mRNA processing and chromatin modulation suggests altered transcriptional 358 359 regulation and DNA replication in TP53 mutated MM, which is similar to findings in other cancers<sup>9,18,24,25</sup>. 360

361 When exploring potential confounding genomic factors that may contribute to the enhanced 362 drug sensitivity profile in TP53 mutated MM cells, we noticed that TP53 mutations were frequently accompanied by KRAS mutations, which was not observed in monoallelic TP53 363 364 MM. However, when we compared the drug response profiles of samples with TP53 mutation and WT KRAS to samples with both TP53 and KRAS mutation, we only found 5 drugs were 365 significantly affected by the presence of a KRAS mutation, with the KRAS mutation conferring 366 a slight negative effect on the activity of these drugs. These results indicate that mutation to 367 TP53 is the main contributor to the enhanced drug sensitivity and altered transcriptomic and 368 369 proteomic profiles of TP53 mutated cells. Further research is needed to understand the 370 mechanisms leading to enhanced sensitivity to drugs such as plicamycin and doxorubicin and

371 their impact on MM cells and disease models with mutated TP53. Additionally, other drugs that were not included in our panel could be effective for patients with TP53 mutation positive 372 373 MM. For example, our proteomic analysis showed elevated levels of XPO1, the target of 374 approved MM drug selinexor, and its cofactor RANBP3, which are exclusively responsible for transporting p53 out of the nucleus<sup>26,27</sup>. Considering the enhanced activity of several 375 chemotherapies in TP53 mutated CD138+ MM cells, newer agents such as the antibody-drug 376 conjugate blenrep and peptide-drug conjugate melflufen might also provide increased efficacy 377 378 for patients with TP53 mutated MM. In addition, novel therapeutic approaches, such as CAR-379 T cell therapies, bispecific and monoclonal antibodies have shown promising results for MM 380 in clinical settings<sup>28</sup>. Our drug screening, however, was limited to small molecules, which were 381 tested, depending on cell availability, on isolated CD138+ MM cells without the supporting 382 immune microenvironment. Nevertheless, the results revealed targetable vulnerabilities in *TP53* mutated MM, which could be investigated further for future therapeutic development. 383

384 While our comprehensive profiling showed that mutation to TP53 can impact ex vivo drug 385 response as well as the transcriptomic and proteomic profiles to cells with the mutation, we 386 have only recently gained understanding of the significance of this aberration on patient 387 outcome. The adverse effect of TP53 mutation on overall survival suggests that early detection of subclonal TP53 mutations could potentially predict faster disease progression after relapse 388 389 and allow for earlier intervention. This would be particularly important for patients without 390 del(17p) but with mutated TP53, as these patients may not be correctly stratified and are less likely to receive optimized care. 391

392 In conclusion, our study offers translational insights into the implications of TP53 mutations in 393 MM. Our findings elucidate key molecular aspects from genomic to proteomic landscapes, 394 guiding future research and therapeutic strategies for this subgroup of patients. As the 395 complexities of MM continue to be unraveled with the application of advanced technologies, 396 we will gain better understanding of the impact of genetic mutations like TP53, and how these can shape the future of MM risk-stratification and treatment. These findings emphasize the 397 398 importance of personalized medicine approaches in oncology and provide rationale for the 399 development of multiple therapeutic strategies and treatment of TP53 mutated MM.

400

401 **FIGURE LEGENDS** 

402 **Table 1.** Summarized characteristics of MM patients providing samples to the FIMM cohort

403 and the analyses performed.

404 **Table 2**. *TP53* mutations detected in patients from the FIMM dataset.

Figure 1. Workflow and patient stratification according to *TP53* status. (A) CD138+ cells from
167 bone marrow samples were molecularly and functionally profiled depending on viable
cell numbers. (B) Dataset used from the MMRF-CoMMpass study for validation purposes. (C)
Comparison of patient *TP53* status with and without DNA sequencing in the MMRFCoMMpass patient population. Remaining patient proportion in grey represents wild-type
(WT) *TP53* status.

411 Figure 2. Ex vivo drug screening identifies compounds with enhanced activity in MM patient 412 samples with TP53 mutation. (A) Volcano plot illustrating the comparison of drug sensitivity 413 between MM samples with monoallelic TP53 and WT TP53 samples. No compounds 414 presented significantly increased sensitivity for samples with monoallelic TP53. (B) Samples 415 harboring TP53 mutations, irrespective of del(17p) status, exhibit increased sensitivity to a 416 range of therapeutic agents. The volcano plot's x-axis shows the median difference in DSS 417 between the two groups, while the y-axis represents the negative logarithm (base10) of the 418 p-value obtained from the Wilcoxon rank-sum test. Data points represent individual 419 compounds, with the datapoint size reflecting the number of samples tested per compound. 420 Significant hits with median difference above 5 are highlighted in red, and a few additional 421 selected compounds are also labeled but remain in grey. (C) Box plot showing the distribution 422 of ex vivo sensitivity to selected compounds. DSS below 10 indicates overall resistance to the 423 compounds. The center line represents the median value. The upper and lower limits of the 424 box represent the upper (75th percentile) and lower (25th percentile) quartiles, respectively. 425 The whiskers extend to the largest and smallest values within 1.5 times the interquartile range 426 from the quartiles. Points beyond the whiskers are outliers and are plotted individually. 427 Statistical significance indicated as \* p-value < 0.05, \*\* p-value < 0.01, \*\*\* p-value < 0.001 by 428 Wilcoxon rank-sum test.

Figure 3. Co-occurrence of other mutations in addition to *TP53* aberrations. (A) Heatmap of common mutations in samples with *TP53* aberrations from the FIMM cohort. *KRAS* mutations in samples with *TP53* mutation are overrepresented compared to del(17p) alone. (B) Heatmap of common mutations in patients containing *TP53* aberrations from the MMRF-CoMMpass study dataset. (C) Frequency of mutations in the *TP53* coding region from 52 patients of the

434 MMRF-CoMMpass study according to available data. The illustration of the functional domains in the p53 protein includes the transcriptional activation domains (TAD, in blue and 435 436 green), the DNA binding domain (DBD, in red) and the tetramerization domain (TD, in orange). 437 Figure 4. Genes sets associated with cellular proliferation are enriched in TP53 mutated MM. (A) Differential gene expression (DGE) in TP53 mutated MM samples compared to WT TP53 438 439 samples from the FIMM dataset. The x-axis shows the log2 fold change in expression and the 440 y-axis shows the negative log10 of the p-value. Red dots represent genes with increased 441 expression in TP53 mutated MM, while decreased expression is represented with blue dots. 442 (B) DGE analysis from the CoMMpass dataset, represented similarly, however the y-axis shows 443 the negative log10 of the adjusted p-value. (C) Gene set enrichment analysis (GSEA) results 444 compared between both datasets, ordered by normalized enrichment score (NES) of the 445 FIMM dataset. The gene sets shown have an adjusted p-value  $\leq 0.1$  in at least one of the two 446 datasets. (D) GSEA network plot illustrating the relationship between differentially expressed 447 genes from selected hallmark gene sets. The genes shown are differentially expressed in 448 CoMMpass dataset.

449 Figure 5. Proteins involved in RNA processing are more prevalent in *TP53* mutated MM cells. 450 (A) Significantly increased expression of proteins from samples with TP53 mutation compared 451 to WT TP53 samples is represented in a volcano plot. The x-axis shows the difference in the 452 mean level of protein expression, with the y-axis representing negative log10 of the p-value. 453 Red dots represent genes with increased expression in TP53 mutated MM, while decreased 454 expression is represented with blue dots. (B) GSEA of significant proteins on the hallmarks 455 database reaffirm the results from the gene expression analysis, which showed gene sets 456 associated with increased proliferation are enriched in TP53 mutated MM. (C) The ten most 457 positively and five most negatively enriched gene sets on GO C5 database. Gene sets are presented in descending order of normalized enrichment score (NES). (D) Analysis shows 458 459 significant reduction in survival for patients with TP53 mutation compared to WT TP53 (OS: 2.004 [95% CI: 1.314-3.057] p = 0.001). Monoallelic loss of TP53 (cut-off ≥ 20%) suggests a 460 comparatively better prognosis (OS: HR = 1.264 [95% CI: 0.681-2.343] p = 0.458). (E) 461 Monoallelic loss of TP53, with presence of WT TP53 shows short progression free survival 462 (PFS) of 530 days (PFS: HR = 1.356 [95% CI: 0.997-1.846] p = 0.053). On the other hand, 463 464 presence of TP53 mutation shows a delayed median progression 628 days (PFS: HR = 1.024 465 [95% CI: 0.832-1.260] p = 0.823), WT patients' median PFS was 689 days.

466

### 467 **ACKNOWLEDGMENTS**

The authors thank the patients for their consent and generosity to use their samples and data. We are grateful for the support of the FIMM Technology Center Genomics and High Throughput Biomedicine Units. In addition, we thank the Multiple Myeloma Research Foundation (MMRF) for making their datasets publicly available. The Finnish Hematology Registry and Biobank and the Helsinki Hematology Research Unit are acknowledged for contributions to the sample collection and clinical data.

474

#### 475 AUTHOR CONTRIBUTIONS

476 C.A.H., D.T., and M.M.M. contributed to the study conceptualization. D.T., J.M., A.P., M.S., and 477 M.M.M. performed experimental work. S.E. performed data normalizations for proteomic and 478 sequencing data. K.D., P.D., D.B. and P.O'G. performed LC-MS/MS experiments and 479 contributed to proteomics data analysis. D.T. performed data analysis and interpretation with 480 N.I.'s contribution. J.L., R.S. and P.A. provided patient samples and contributed clinical data. D.T., J.J.M., I.V., N.I. and C.A.H. contributed to data management. D.T. and C.A.H. wrote the 481 482 article. C.A.H. supervised the study and provided infrastructure support. All authors critically read and approved the final version of the article. 483

484

## 485 CONFLICTS OF INTEREST

C.A.H has received funding from BMS/Celgene, Kronos Bio, Novartis, Oncopeptides,
WNTResearch, and Zentalis Pharmaceuticals for research unrelated to this work, and
honorarium from Amgen and Autolus. R.S. has received research funding from Amgen,
BMS/Celgene and Takeda administered by Hospital Science Centers, unrelated to this work.
All other authors declare no conflicts of interest.

491

#### 492 **REFERENCES**

493 1. Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a

494 glance into future. *Haematologica*. 2020;105(10):2358–2367.

495 2. Wiedmeier-Nutor JE, Bergsagel PL. Review of Multiple Myeloma Genetics including 496 Effects on Prognosis, Response to Treatment, and Diagnostic Workup. Life (Basel). 497 2022;12(6):812. 498 3. Corre J, Perrot A, Caillot D, et al. del(17p) without TP53 mutation confers a poor 499 prognosis in intensively treated newly diagnosed patients with multiple myeloma. Blood. 500 2021;137(9):1192–1195. 4. Chavan SS, He J, Tytarenko R, et al. Bi-allelic inactivation is more prevalent at relapse in 501 502 multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J. 503 2017;7(2):e535. 504 5. Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, Double-Hit, group of newly 505 diagnosed myeloma identified by genomic analysis. *Leukemia*. 2019;33(1):159–170. 506 6. Flynt E, Bisht K, Sridharan V, et al. Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma. Cells. 2020;9(2):287. 507 508 7. Weinhold N, Ashby C, Rasche L, et al. Clonal selection and double-hit events involving 509 tumor suppressor genes underlie relapse in myeloma. *Blood*. 2016;128(13):1735–1744. 510 8. Corre J, Munshi NC, Avet-Loiseau H. Risk factors in multiple myeloma: is it time for a 511 revision? *Blood*. 2021;137(1):16–19. 512 9. Chen X, Zhang T, Su W, et al. Mutant p53 in cancer: from molecular mechanism to 513 therapeutic modulation. *Cell Death Dis.* 2022;13(11):1–14. 514 10. Majumder MM, Silvennoinen R, Anttila P, et al. Identification of precision treatment 515 strategies for relapsed/ refractory multiple myeloma by functional drug sensitivity 516 testing. Oncotarget. 2017;8(34):56338-56350. 517 11. Malani D, Kumar A, Brück O, et al. Implementing a Functional Precision Medicine Tumor 518 Board for Acute Myeloid Leukemia. Cancer Discov. 2022;12(2):388-401. 12. Kuusanmäki H, Kytölä S, Vänttinen I, et al. Ex vivo venetoclax sensitivity testing predicts 519 520 treatment response in acute myeloid leukemia. *Haematologica*. 2023;108(7):1768–1781. 13. Kropivsek K, Kachel P, Goetze S, et al. Ex vivo drug response heterogeneity reveals 521 522 personalized therapeutic strategies for patients with multiple myeloma. Nat Cancer. 2023;4(5):734-753. 523 14. Gencel-Augusto J, Lozano G. p53 tetramerization: at the center of the dominant-negative 524 525 effect of mutant p53. Genes Dev. 2020;34(17-18):1128-1146.

526 15. Yadav B, Pemovska T, Szwajda A, et al. Quantitative scoring of differential drug sensitivity

527 for individually optimized anticancer therapies. *Sci Rep*. 2014;4(1):5193.

528 16. Richardson PG, Mitsiades CS, Laubach JP, et al. Inhibition of heat shock protein 90

529 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.

530 British Journal of Haematology. 2011;152(4):367–379.

531 17. Martello M, Poletti A, Borsi E, et al. Clonal and subclonal TP53 molecular impairment is

associated with prognosis and progression in multiple myeloma. *Blood Cancer J.* 

533 2022;12(1):15.

18. Hu J, Cao J, Topatana W, et al. Targeting mutant p53 for cancer therapy: direct and
indirect strategies. *Journal of Hematology & Oncology*. 2021;14(1):157.

19. Lindström MS, Bartek J, Maya-Mendoza A. p53 at the crossroad of DNA replication and
ribosome biogenesis stress pathways. *Cell Death Differ*. 2022;29(5):972–982.

538 20. Werner H, LeRoith D. Hallmarks of cancer: The insulin-like growth factors perspective.
539 *Front. Oncol.* 2022;12:1055589.

540 21. Cui D, Qu R, Liu D, et al. The Cross Talk Between p53 and mTOR Pathways in Response to
541 Physiological and Genotoxic Stresses. *Front. Cell Dev. Biol.* 2021;9:775507.

542 22. Kang J, Brajanovski N, Chan KT, et al. Ribosomal proteins and human diseases: molecular
543 mechanisms and targeted therapy. *Sig Transduct Target Ther*. 2021;6(1):1–22.

544 23. Burger K, Mühl B, Harasim T, et al. Chemotherapeutic drugs inhibit ribosome biogenesis
545 at various levels. *J Biol Chem*. 2010;285(16):12416–12425.

546 24. Bhakat KK, Ray S. The FAcilitates Chromatin Transcription (FACT) complex: Its roles in

547 DNA repair and implications for cancer therapy. *DNA Repair*. 2022;109:103246.

548 25. Zhu J, Sammons MA, Donahue G, et al. Gain-of-function p53 mutants co-opt chromatin
549 pathways to drive cancer growth. *Nature*. 2015;525(7568):206–211.

550 26. Golomb L, Bublik DR, Wilder S, et al. Importin 7 and exportin 1 link c-Myc and p53 to

regulation of ribosomal biogenesis. *Mol Cell*. 2012;45(2):222–232.

552 27. Azmi AS, Uddin MH, Mohammad RM. The nuclear export protein XPO1 — from biology
553 to targeted therapy. *Nat Rev Clin Oncol*. 2021;18(3):152–169.

28. Rasche L, Hudecek M, Einsele H. CAR T-cell therapy in multiple myeloma: mission

555 accomplished? *Blood*. 2024;143(4):305–310.

- 29. Ross FM, Avet-Loiseau H, Ameye G, et al. Report from the European Myeloma Network
- 557 on interphase FISH in multiple myeloma and related disorders. *Haematologica*.
- 558 2012;97(8):1272–1277.
- 30. Karjalainen R, Pemovska T, Popa M, et al. JAK1/2 and BCL2 inhibitors synergize to
- 560 counteract bone marrow stromal cell–induced protection of AML. *Blood*.
- 561 2017;130(6):789–802.
- 31. Kontro M, Kuusanmäki H, Eldfors S, et al. Novel activating STAT5B mutations as putative
  drivers of T-cell acute lymphoblastic leukemia. *Leukemia*. 2014;28(8):1738–1742.
- 564 32. Eldfors S, Kuusanmäki H, Kontro M, et al. Idelalisib sensitivity and mechanisms of disease
   565 progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. *Leukemia*.
- 566 2017;31(1):51–57.
- 567 33. Kumar A, Kankainen M, Parsons A, et al. The impact of RNA sequence library
- 568 construction protocols on transcriptomic profiling of leukemia. *BMC Genomics*.569 2017;18(1):629.
- 570 34. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
  571 RNA-seq data with DESeq2. *Genome Biology*. 2014;15(12):550.
- 572 35. Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting
  573 omics data. *Innovation*. 2021;2(3):.
- 574 36. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A
- 575 knowledge-based approach for interpreting genome-wide expression profiles.
- 576 *Proceedings of the National Academy of Sciences*. 2005;102(43):15545–15550.
- 577 37. Liberzon A, Subramanian A, Pinchback R, et al. Molecular signatures database (MSigDB)
  578 3.0. *Bioinformatics*. 2011;27(12):1739–1740.
- 579 38. Goldsmith SR, Fiala MA, Dukeman J, et al. Next Generation Sequencing-based Validation
- 580 of the Revised International Staging System for Multiple Myeloma: An Analysis of the
- 581 MMRF CoMMpass Study. Clinical Lymphoma Myeloma and Leukemia. 2019;19(5):285–
- 582 289.
- 583 39. Therneau T. A package for survival analysis in R. 2020;
- 40. Kassambara A, Kosinski M, Biecek P, Fabian S. survminer: Drawing Survival Curves using
  "ggplot2." 2021;





```
Figure 2
```



# Figure 3

25







# Figure 4



# Figure 5



			Monoallelic TP53	TP53 mutation	WT <i>TP5</i> 3 (n=	
		Total (n = 167)	(n = 19; 11.4%)	(n = 18; 10.8%)	130; 77.8%)	P value
Median age (range)		67 (26-84)	67 (49-80)	67,5 (57-78)	66 (26-84)	0.921
Gender						0.103
	Male, n (%)	97 (58.1)	7 (36.8)	14 (77.8)	76 (58.5)	
	Female, n (%)	70 (41.9)	12 (63.2)	4 (22.2)	54 (41.5)	
Disease stage						0.006
	Diagnosis, n (%)	69 (41.3)	4 (21.1)	3 (16.7)	62 (47.7)	
	Relapse, n (%)	98 (58.7)	15 (78.9)	15 (83.3)	68 (52.3)	
Cytogenetics						
	del(17p), n (%)	26 (15.6)	19 (100)	7 (38.9)	0 (0.0)	0
	t(11;14), n (%)	30 (18.0)	2 (10.5)	2(11.1)	26 (20.0)	0.556
	t(4;14), n (%)	16 (9.6)	4 (21.1)	0 (0.0)	12 (9.2)	0.081
	t(14;16), n (%)	2 (1.2)	1 (5.3)	0 (0.0)	1 (0.8)	0.395
	del(13q)/-13, n (%)	57 (34.1)	14 (73.7)	4 (22.2)	39 (30.0)	0.001
	1q gain, n (%)	57 (34.1)	12 (63.2)	6 (33.3)	39 (30.0)	0.017
	Not available, n (%)	41 (24.6)	0 (0.0)	5 (27.8)	36 (27.7)	0.014
Ex vivo drug screening		153 (91.6)	18 (94.7)	15 (78.9)	120 (92.3)	0.27
DNA sequencing, n (%)		135 (80.8)	14 (73.6)	18 (100)	103 (79.2)	0.052
RNA sequencing, n (%)		98 (58.7)	6 (31.6)	15 (83.3)	77 (59.2)	0.005
Proteomics, n (%)		34 (20.4)	6 (31.6)	5 (27.7)	23 (17.7)	0.265

Table 1. Summarized characteristics of MM patients providing samples to the FIMM cohort and the analyses performed.

Sample ID	Disease stage	del(17p)	<b>Mutation Frequency in Tumor</b>	Somatic P-Value	<b>Chromosome Location</b>	Base Change	Amino Acid Change	Variant Effect	Protein Domain
MM005_2	Relapse	Yes	0.2222	0.041812	Chr17:7572961	A>G	L383P	non synonymous coding	Regulatory Domain
MM007_1	Relapse	No	0.3359	1.2718e-14	Chr17:7577534	C>A	R249S	non synonymous coding	DNA-Binding Domain
MM010_1	Relapse	Yes	0.86	8.4891e-24	Chr17:7578185	GC>G	-221	frame shift	
MM025_1	Relapse	Yes	0.4175	3.5168e-17	Chr17:7577574	T>C	Y236C	non synonymous coding	DNA-Binding Domain
MM033_4	Relapse	Yes	0.2087	2.591e-05	Chr17:7578371	C>G	G187R	non synonymous coding	DNA-Binding Domain
MM041_1	Relapse	Yes	0.5833	6.9734e-07	Chr17:7577518	TGATGGTGAG>T	LTI252-	codon deletion	
MM042_1	Relapse	Yes	0.7536	1.2896e-12	Chr17:7577535	C>A	R249M	non synonymous coding	DNA-Binding Domain
MM043_2	Relapse	Yes	0.7857	4.8947e-29	Chr17:7578242	C>G	V203L	non synonymous coding	DNA-Binding Domain
MM043_2	Relapse	Yes	0.125	0.0034623	Chr17:7578204	A>C	S215R	non synonymous coding	DNA-Binding Domain
MM055_1	Relapse	No	0.6436	1.7451e-24	Chr17:7578440	T>C	K164E	non synonymous coding	DNA-Binding Domain
MM060_2	Relapse	No	0.1314	0.00056092	Chr17:7577538	C>T	R248Q	non synonymous coding	DNA-Binding Domain
MM064_1	Diagnosis	No	0.4667	1.0176e-05	Chr17:7578190	T>C	Y220C	non synonymous coding	DNA-Binding Domain
MM064_1	Diagnosis	No	0.434	0.00016009	Chr17:7578176	C>A		splice site donor	
MM065_1	Diagnosis	Yes	0.1296	0.0016255	Chr17:7577022	G>A	R306*	stop gained	DNA-Binding Domain
MM085_2	Relapse	No	0.3265	1.0205e-06	Chr17:7574034	C>G	c.994-1G>C	splice acceptor variant+intron variant	
MM098_1	Relapse	Yes	0.623	1.9092e-17	Chr17:7578291	T>C		splice site acceptor	DNA-Binding Domain
MM107_1	Relapse	Yes	0.6579	9.7397e-14	Chr17:7579529	C>T	p.Trp53*/c.158G>A	stop gained	DNA-Binding Domain
MM122_1	Diagnosis	No	0.0929	0.011409	Chr17:7578433	G>T	S166*	stop gained	DNA-Binding Domain
MM135_1	Relapse	Yes	0.9478	3.7734e-39	Chr17:7578479	G>T	P151T	non synonymous coding	DNA-Binding Domain
MM137_1	Relapse	No	0.3817	9.5371e-10	Chr17:7577506	C>G	D259H	non synonymous coding	DNA-Binding Domain